SG Americas Securities LLC Has $233,000 Stock Position in Blueprint Medicines Co. (NASDAQ:BPMC)

SG Americas Securities LLC trimmed its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 88.4% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,521 shares of the biotechnology company's stock after selling 19,163 shares during the period. SG Americas Securities LLC's holdings in Blueprint Medicines were worth $233,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Triad Wealth Partners LLC acquired a new stake in Blueprint Medicines in the 2nd quarter valued at $27,000. Covestor Ltd lifted its holdings in Blueprint Medicines by 9,700.0% in the 1st quarter. Covestor Ltd now owns 294 shares of the biotechnology company's stock worth $28,000 after buying an additional 291 shares in the last quarter. Headlands Technologies LLC boosted its holdings in Blueprint Medicines by 105.2% in the first quarter. Headlands Technologies LLC now owns 667 shares of the biotechnology company's stock valued at $63,000 after purchasing an additional 342 shares during the last quarter. Natixis acquired a new stake in Blueprint Medicines during the 1st quarter valued at approximately $73,000. Finally, CWM LLC boosted its stake in shares of Blueprint Medicines by 114.6% during the 2nd quarter. CWM LLC now owns 1,105 shares of the biotechnology company's stock valued at $119,000 after buying an additional 590 shares during the last quarter.

Blueprint Medicines Stock Performance

Shares of NASDAQ BPMC traded up $0.86 during trading hours on Tuesday, reaching $86.47. The stock had a trading volume of 731,773 shares, compared to its average volume of 688,802. The company has a market cap of $5.41 billion, a price-to-earnings ratio of -17.97 and a beta of 0.58. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.71 and a quick ratio of 3.65. The business's fifty day moving average is $90.32 and its two-hundred day moving average is $98.80. Blueprint Medicines Co. has a twelve month low of $43.89 and a twelve month high of $121.90.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last released its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.80) earnings per share for the quarter, beating the consensus estimate of ($1.29) by $0.49. The company had revenue of $138.20 million for the quarter, compared to analyst estimates of $104.02 million. Blueprint Medicines had a negative return on equity of 157.30% and a negative net margin of 56.64%. The company's revenue was up 139.9% compared to the same quarter last year. During the same period in the prior year, the company posted ($2.19) EPS. As a group, research analysts expect that Blueprint Medicines Co. will post -3.99 EPS for the current year.

Insider Activity

In other Blueprint Medicines news, insider Philina Lee sold 41,913 shares of the company's stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $93.19, for a total transaction of $3,905,872.47. Following the sale, the insider now directly owns 34,729 shares of the company's stock, valued at approximately $3,236,395.51. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, insider Philina Lee sold 41,913 shares of the firm's stock in a transaction on Monday, August 5th. The stock was sold at an average price of $93.19, for a total value of $3,905,872.47. Following the completion of the sale, the insider now directly owns 34,729 shares in the company, valued at approximately $3,236,395.51. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Fouad Namouni sold 3,633 shares of the company's stock in a transaction dated Thursday, October 3rd. The stock was sold at an average price of $89.32, for a total transaction of $324,499.56. Following the transaction, the insider now owns 69,070 shares in the company, valued at approximately $6,169,332.40. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 4.21% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. Needham & Company LLC reissued a "buy" rating and issued a $130.00 target price on shares of Blueprint Medicines in a research report on Thursday, August 1st. Baird R W raised Blueprint Medicines to a "strong-buy" rating in a report on Friday, August 2nd. Oppenheimer boosted their price target on Blueprint Medicines from $114.00 to $125.00 and gave the company an "outperform" rating in a report on Monday, July 8th. Barclays raised their price objective on Blueprint Medicines from $75.00 to $105.00 and gave the stock an "equal weight" rating in a research note on Monday, July 29th. Finally, Robert W. Baird boosted their target price on shares of Blueprint Medicines from $112.00 to $127.00 and gave the company an "outperform" rating in a research note on Friday, August 2nd. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $120.00.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.